Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

01-06-2014 | Original Article

Twins in spirit part II: DOTATATE and high-affinity DOTATATE—the clinical experience

Authors: Claudia Brogsitter, Klaus Zöphel, Holger Hartmann, Margret Schottelius, Hans-Jürgen Wester, Jörg Kotzerke

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 6/2014

Abstract

Purpose

Over recent decades interest in diagnosis and treatment of neuroendocrine tumours (NET) has steadily grown. The basis for diagnosis and therapy of NET with radiolabelled somatostatin (hsst) analogues is the variable overexpression of hsst receptors (hsst1–5 receptors). We hypothesized that radiometal derivatives of DOTA-iodo-Tyr³-octreotide analogues might be excellent candidates for somatostatin receptor imaging. We therefore explored the diagnostic potential of ⁶⁸Ga-DOTA-iodo-Tyr³-octreotate [⁶⁸Ga-DOTA,3-iodo-Tyr³,Thr⁸]octreotide (⁶⁸Ga-HA-DOTATATE; HA, high-affinity) compared to the established ⁶⁸Ga-DOTA-Tyr³-octreotate (⁶⁸Ga-DOTATATE) in vivo.

Methods

The study included 23 patients with known somatostatin receptor-positive metastases from NETs, thyroid cancer or glomus tumours who were investigated with both ⁶⁸Ga-HA-DOTATATE and ⁶⁸Ga-DOTATATE. A patient-based and a lesion-based comparative analysis was carried out of normal tissue distribution and lesion detectability in a qualitative and a semiquantitative manner.

Results

⁶⁸Ga-HA-DOTATATE and ⁶⁸Ga-DOTATATE showed comparable uptake in the liver (SUV_mean 8.9 ± 2.2 vs. 9.3 ± 2.5, n.s.), renal cortex (SUV_mean 13.3 ± 3.9 vs. 14.5 ± 3.7, n.s.) and spleen (SUV_mean 24.0 ± 6.7 vs. 22.9 ± 7.3, n.s.). A somewhat higher pituitary uptake was found with ⁶⁸Ga-HA-DOTATATE (SUV_mean 6.3 ± 1.8 vs. 5.4 ± 2.1, p < 0.05). On a lesion-by-lesion basis a total of 344 lesions were detected. ⁶⁸Ga-HA-DOTATATE demonstrated 328 lesions (95.3 % of total lesions seen), and ⁶⁸Ga-DOTATATE demonstrated 332 lesions (96.4 %). The mean SUV_max of all lesions was not significantly different between ⁶⁸Ga-HA-DOTATATE and ⁶⁸Ga-DOTATATE (17.8 ± 11.4 vs. 16.7 ± 10.7, n.s.).

Conclusion

Our analysis demonstrated very good concordance between ⁶⁸Ga-HA-DOTATATE and ⁶⁸Ga-DOTATATE PET data. As the availability and use of ⁶⁸Ga-HA-DOTATATE is not governed by patent restrictions it may be an attractive alternative to other ⁶⁸Ga-labelled hsst analogues.

Atkinson H, England JA, Rafferty A, Jesudason V, Bedford K, Karsai L, et al. Somatostatin receptor expression in thyroid disease. Int J Exp Pathol. 2013;94:226–9. doi:10.1111/iep.12024.PubMedCrossRef

Kaemmerer D, Peter L, Lupp A, Schulz S, Sanger J, Prasad V, et al. Molecular imaging with 68Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2011;38:1659–68. doi:10.1007/s00259-011-1846-5.PubMedCrossRef

Lamberts SW, Bakker WH, Reubi JC, Krenning EP. Somatostatin-receptor imaging in the localization of endocrine tumors. N Engl J Med. 1990;323:1246–9.PubMedCrossRef

Kwekkeboom DJ, Bakker WH, Kam BL, Teunissen JJ, Kooij PP, de Herder WW, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0), Tyr3]octreotate. Eur J Nucl Med Mol Imaging. 2003;30:417–22. doi:10.1007/s00259-002-1050-8.PubMedCentralPubMedCrossRef

Krenning EP, Bakker WH, Breeman WA, Koper JW, Kooij PP, Ausema L, et al. Localisation of endocrine-related tumours with radioiodinated analogue of somatostatin. Lancet. 1989;1:242–4.PubMedCrossRef

Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel M, et al. Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging. 2010;37:2004–10. doi:10.1007/s00259-010-1512-3.PubMedCrossRef

Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med. 2000;27:273–82.PubMedCrossRef

Ginj M, Schmitt JS, Chen J, Waser B, Reubi JC, de Jong M, et al. Design, synthesis, and biological evaluation of somatostatin-based radiopeptides. Chem Biol. 2006;13:1081–90. doi:10.1016/j.chembiol.2006.08.012.PubMedCrossRef

Brogsitter C, Schottelius M, Zophel K, Kotzerke J, Wester HJ. Twins in spirit: DOTATATE and high-affinity DOTATATE. Eur J Nucl Med Mol Imaging. 2013;40:1789. doi:10.1007/s00259-013-2497-5.PubMedCrossRef

10.

Krenning EP, Bakker WH, Kooij PP, Breeman WA, Oei HY, de Jong M, et al. Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide. J Nucl Med. 1992;33:652–8.PubMed

11.

Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schafer M, et al. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2007;34:1617–26. doi:10.1007/s00259-007-0450-1.PubMedCrossRef

12.

Hartmann H, Zophel K, Freudenberg R, Oehme L, Andreeff M, Wunderlich G, et al. Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations. Nuklearmedizin. 2009;48:201–7. doi:10.3413/nukmed-0214.PubMed

13.

Kowalski J, Henze M, Schuhmacher J, Macke HR, Hofmann M, Haberkorn U. Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. Mol Imaging Biol. 2003;5:42–8.PubMedCrossRef

14.

Virgolini IJ, Gabriel M, von Guggenberg E, Putzer D, Kendler D, Decristoforo C. Role of radiopharmaceuticals in the diagnosis and treatment of neuroendocrine tumours. Eur J Cancer. 2009;45 Suppl 1:274–91. doi:10.1016/S0959-8049(09)70042-5.PubMedCrossRef

15.

Ben-Shlomo A, Melmed S. Pituitary somatostatin receptor signaling. Trends Endocrinol Metab. 2010;21:123–33. doi:10.1016/j.tem.2009.12.003.PubMedCentralPubMedCrossRef

16.

Hofland LJ, Feelders RA, de Herder WW, Lamberts SW. Pituitary tumours: the sst/D2 receptors as molecular targets. Mol Cell Endocrinol. 2010;326:89–98. doi:10.1016/j.mce.2010.04.020.PubMedCrossRef

17.

Kabasakal L, Demirci E, Ocak M, Decristoforo C, Araman A, Ozsoy Y, et al. Comparison of 68Ga-DOTATATE and 68Ga-DOTANOC PET/CT imaging in the same patient group with neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012;39:1271–7.PubMedCrossRef

18.

Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, et al. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors. J Nucl Med. 2011;52:1864–70.PubMedCrossRef

19.

Wild D, Bomanji JB, Benkert P, Maecke H, Ell PJ, Reubi JC, et al. Comparison of 68Ga-DOTANOC and 68Ga-DOTATATE PET/CT within patients with gastroenteropancreatic neuroendocrine tumors. J Nucl Med. 2013;54:364–72.PubMedCrossRef

20.

Putzer D, Kroiss A, Waitz D, Gabriel M, Traub-Weidinger T, Uprimny C, et al. Somatostatin receptor PET in neuroendocrine tumours: 68Ga-DOTA0, Tyr3-octreotide versus 68Ga-DOTA0-lanreotide. Eur J Nucl Med Mol Imaging. 2013;40:364–72. doi:10.1007/s00259-012-2286-6.PubMedCrossRef

21.

Demirci E, Ocak M, Kabasakal L, Araman A, Ozsoy Y, Kanmaz B. Comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-LAN PET/CT imaging in the same patient group with neuroendocrine tumours: preliminary results. Nucl Med Commun. 2013;34:727–32. doi:10.1097/MNM.0b013e328362cca6.PubMedCrossRef

22.

Naswa N, Sharma P, Suman Kc S, Lata S, Kumar R, Malhotra A, et al. Prospective evaluation of 68Ga-DOTA-NOC PET-CT in patients with recurrent medullary thyroid carcinoma: comparison with 18F-FDG PET-CT. Nucl Med Commun. 2012;33:766–74. doi:10.1097/MNM.0b013e3283541157.PubMedCrossRef

23.

Shastry M, Kayani I, Wild D, Caplin M, Visvikis D, Gacinovic S, et al. Distribution pattern of 68Ga-DOTATATE in disease-free patients. Nucl Med Commun. 2010;31:1025–32.PubMed

24.

Vanhagen PM, Krenning EP, Reubi JC, Kwekkeboom DJ, Bakker WH, Mulder AH, et al. Somatostatin analogue scintigraphy in granulomatous diseases. Eur J Nucl Med. 1994;21:497–502.PubMedCrossRef

25.

Mussig K, Oksuz MO, Pfannenberg C, Adam P, Zustin J, Beckert S, et al. Somatostatin receptor expression in an epitheloid hemangioma causing oncogenic osteomalacia. J Clin Endocrinol Metab. 2009;94:4123–4.PubMedCrossRef

26.

Winter PF, Lapke J, Winek R. Subcutaneous cavernous hemangioma visualized on an indium-111-octreotide scan. J Nucl Med. 1996;37:1516–7.PubMed

Title: Twins in spirit part II: DOTATATE and high-affinity DOTATATE—the clinical experience
Authors: Claudia Brogsitter
Klaus Zöphel
Holger Hartmann
Margret Schottelius
Hans-Jürgen Wester
Jörg Kotzerke
Publication date: 01-06-2014
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 6/2014
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-014-2690-1

ACC 2024 Congress

Springer Medicine

Twins in spirit part II: DOTATATE and high-affinity DOTATATE—the clinical experience

Abstract

Purpose

Methods

Results

Conclusion

ACC 2024 Congress

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 6/2014

18F-FLT and 18F-FDOPA PET kinetics in recurrent brain tumors

FDG PET/CT in autoimmune pancreatitis

PET/MR attenuation correction: where have we come from and where are we going?

Cross sectional PET study of cerebral adenosine A1 receptors in premanifest and manifest Huntington’s disease

FDG PET during radiochemotherapy is predictive of outcome at 1 year in non-small-cell lung cancer patients: a prospective multicentre study (RTEP2)

Staging the axilla in breast cancer patients with 18F-FDG PET: how small are the metastases that we can detect with new generation clinical PET systems?